Literature DB >> 17085483

Haplotype-specific expression of exon 10 at the human MAPT locus.

Tara M Caffrey1, Catharine Joachim, Silvia Paracchini, Margaret M Esiri, Richard Wade-Martins.   

Abstract

Neurofibrillary tangles composed of exon 10+ microtubule associated protein tau (MAPT) deposits are the characteristic feature of the neurodegenerative diseases progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). PSP, CBD and more recently Alzheimer's disease and Parkinson's disease, are associated with the MAPT H1 haplotype, but the relationship between genotype and disease remains unclear. Here, we investigate the hypothesis that H1 expresses more exon 10+ MAPT mRNA compared to the other haplotype, H2, leading to a greater susceptibility to neurodegeneration in H1 carriers. We performed allele-specific gene expression on two H1/H2 heterozygous human neuronal cell lines, and 14 H1/H2 heterozygous control individual post-mortem brain tissue from two brain regions. In both tissue culture and post-mortem brain tissue, we show that the MAPT H1 haplotype expresses significantly more exon 10+ MAPT mRNA than H2. In post-mortem brain tissue, we show that the total level of MAPT expression from H1 and H2 is not significantly different, but that the H1 chromosome expresses up to 1.43-fold more exon 10+ MAPT mRNA than H2 in the globus pallidus, a brain region highly affected by tauopathy (maximum exon 10+ MAPT H1:H2 transcript ratio=1.425, SD=0.205, P<0.0001), and up to 1.29-fold more exon 10+ MAPT mRNA than H2 in the frontal cortex (maximum exon 10+ MAPT H1:H2 transcript ratio=1.291, SD=0.315, P=0.006). These data may explain the increased susceptibility of H1 carriers to neurodegeneration and suggest a potential mechanism between MAPT genetic variability and the pathogenesis of neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085483     DOI: 10.1093/hmg/ddl429

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  57 in total

1.  Tau isoform composition influences rate and extent of filament formation.

Authors:  Qi Zhong; Erin E Congdon; Haikady N Nagaraja; Jeff Kuret
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

Review 2.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

3.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

4.  Genome-wide association study identifies MAPT locus influencing human plasma tau levels.

Authors:  Jason Chen; Jin-Tai Yu; Kevin Wojta; Hui-Fu Wang; Henrik Zetterberg; Kaj Blennow; Jennifer S Yokoyama; Michael W Weiner; Joel H Kramer; Howard Rosen; Bruce L Miller; Giovanni Coppola; Adam L Boxer
Journal:  Neurology       Date:  2017-01-18       Impact factor: 9.910

Review 5.  The genetics of frontotemporal lobar degeneration.

Authors:  Rosa Rademakers; Mike Hutton
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

6.  H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers.

Authors:  Elisa Canu; Marina Boccardi; Roberta Ghidoni; Luisa Benussi; Cristina Testa; Michela Pievani; Matteo Bonetti; Giuliano Binetti; Giovanni B Frisoni
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

7.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

8.  Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons.

Authors:  Pier Paolo Peruzzi; Sean E Lawler; Steve L Senior; Nina Dmitrieva; Pauline A H Edser; Davide Gianni; E Antonio Chiocca; Richard Wade-Martins
Journal:  Mol Ther       Date:  2009-04-07       Impact factor: 11.454

Review 9.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease.

Authors:  Daphne Robakis; Etty Cortes; Lorraine N Clark; Jean Paul G Vonsattel; Tuhin Virmani; Roy N Alcalay; John F Crary; Oren A Levy
Journal:  J Neural Transm (Vienna)       Date:  2016-04-20       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.